TRANSCENTA-B (06628) surged over 10% in late trading. As of press time, the stock was up 8.31% to HK$4.82, with trading volume reaching HK$20.72 million.
On the news front, TRANSCENTA has entered into a strategic cooperation agreement with IVD MEDICAL (01931) regarding potential RWA tokenization of innovative drug pipeline assets. TRANSCENTA will integrate six of its core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, and TST013) into its US entity and utilize IVD MEDICAL's ETHK Global Innovative Drug Intellectual Property RWA Exchange for potential RWA tokenization cooperation.
According to reports, if the token issuance is successful, future funding proceeds will be used to accelerate clinical and preclinical research and development of multiple innovative oncology antibody projects.
Dr. Qian Xueming, Chairman of TRANSCENTA's Board of Directors, stated: "We focus on innovative drug research and development, particularly in the treatment of tumors, osteoporosis, and chronic kidney disease. Drug development is a lengthy, high-risk, high-investment process that requires substantial funding. Through IVD MEDICAL's blockchain-based RWA digital platform, we can package our innovative drug pipeline IP into a US SPV for novel financing, providing us with an entirely new funding channel."
